JP2020510422A - 抗ｔｉｇｉｔ抗体 - Google Patents

抗ｔｉｇｉｔ抗体 Download PDF

Info

Publication number
JP2020510422A
JP2020510422A JP2019546327A JP2019546327A JP2020510422A JP 2020510422 A JP2020510422 A JP 2020510422A JP 2019546327 A JP2019546327 A JP 2019546327A JP 2019546327 A JP2019546327 A JP 2019546327A JP 2020510422 A JP2020510422 A JP 2020510422A
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
sequence identity
tigit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019546327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510422A5 (https=
Inventor
ジュリア シー． ピアセッキ，
ジュリア シー． ピアセッキ，
コートニー ビアーズ，
コートニー ビアーズ，
スコット ピーターソン，
スコット ピーターソン，
ビアンカ プリンツ，
ビアンカ プリンツ，
Original Assignee
シアトル ジェネティックス， インコーポレイテッド
シアトル ジェネティックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シアトル ジェネティックス， インコーポレイテッド, シアトル ジェネティックス， インコーポレイテッド filed Critical シアトル ジェネティックス， インコーポレイテッド
Publication of JP2020510422A publication Critical patent/JP2020510422A/ja
Publication of JP2020510422A5 publication Critical patent/JP2020510422A5/ja
Priority to JP2022118823A priority Critical patent/JP2022141910A/ja
Priority to JP2024026609A priority patent/JP2024057038A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
JP2019546327A 2017-02-28 2018-02-28 抗ｔｉｇｉｔ抗体 Withdrawn JP2020510422A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022118823A JP2022141910A (ja) 2017-02-28 2022-07-26 抗ｔｉｇｉｔ抗体
JP2024026609A JP2024057038A (ja) 2017-02-28 2024-02-26 抗ｔｉｇｉｔ抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762464529P 2017-02-28 2017-02-28
US62/464,529 2017-02-28
US201862616779P 2018-01-12 2018-01-12
US62/616,779 2018-01-12
PCT/US2018/020239 WO2018160704A1 (en) 2017-02-28 2018-02-28 Anti-tigit antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022118823A Division JP2022141910A (ja) 2017-02-28 2022-07-26 抗ｔｉｇｉｔ抗体

Publications (2)

Publication Number Publication Date
JP2020510422A true JP2020510422A (ja) 2020-04-09
JP2020510422A5 JP2020510422A5 (https=) 2021-04-08

Family

ID=63370305

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019546327A Withdrawn JP2020510422A (ja) 2017-02-28 2018-02-28 抗ｔｉｇｉｔ抗体
JP2022118823A Pending JP2022141910A (ja) 2017-02-28 2022-07-26 抗ｔｉｇｉｔ抗体
JP2024026609A Pending JP2024057038A (ja) 2017-02-28 2024-02-26 抗ｔｉｇｉｔ抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022118823A Pending JP2022141910A (ja) 2017-02-28 2022-07-26 抗ｔｉｇｉｔ抗体
JP2024026609A Pending JP2024057038A (ja) 2017-02-28 2024-02-26 抗ｔｉｇｉｔ抗体

Country Status (13)

Country Link
US (3) US20200040082A1 (https=)
EP (1) EP3589313A4 (https=)
JP (3) JP2020510422A (https=)
KR (1) KR20190123749A (https=)
CN (1) CN111050788A (https=)
AU (2) AU2018227489B2 (https=)
BR (1) BR112019017550A2 (https=)
CA (1) CA3053486A1 (https=)
IL (1) IL268517A (https=)
MA (1) MA47694A (https=)
MX (2) MX2019010206A (https=)
SG (2) SG11201907278VA (https=)
WO (1) WO2018160704A1 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3208612B1 (en) 2008-04-09 2019-09-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) * 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
EP3458485B1 (en) 2016-05-19 2021-12-29 The General Hospital Corporation Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
CN110662552A (zh) 2016-11-30 2020-01-07 昂科梅德制药有限公司 包含tigit结合剂的癌症治疗方法
RS64576B1 (sr) 2017-05-01 2023-10-31 Agenus Inc Anti-tigit antitela i postupci njihove primene
IL272227B2 (en) * 2017-07-27 2025-09-01 iTeos Belgium SA Anti-tigit antibodies
JP2021534196A (ja) * 2018-08-23 2021-12-09 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体
US11376255B2 (en) 2018-09-11 2022-07-05 iTeos Belgium SA Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
EP4410375A3 (en) 2018-09-11 2024-11-06 iTeos Belgium SA Thiocarbamate derivatives as a2a inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
CN113614109A (zh) 2018-12-21 2021-11-05 Ose免疫疗法公司 双功能抗pd-1/il-7分子
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
EP3947640A4 (en) 2019-04-02 2022-12-14 The Brigham & Women's Hospital, Inc. PROCEDURE FOR DETERMINING THE PROGRESSION OF PRIMARY MELANOMA
KR102332847B1 (ko) * 2019-06-13 2021-12-01 주식회사 녹십자 Tigit에 대한 항체 및 이의 용도
AU2020298324A1 (en) * 2019-06-21 2022-01-27 Single Cell Technology, Inc. Anti-TIGIT antibodies
AU2020378335A1 (en) * 2019-11-05 2022-04-07 Merck Patent Gmbh Anti-TIGIT antibodies and uses thereof
AU2020406083A1 (en) 2019-12-17 2022-06-16 Boehringer Ingelheim International Gmbh Bifunctional molecules comprising an IL-7 variant
CN112409450B (zh) * 2020-03-29 2023-01-24 郑州大学 TIGIT-IgV的亲和剂及其应用
CN113563470B (zh) 2020-04-29 2023-02-10 广州昂科免疫生物技术有限公司 结合tigit抗原的抗体及其制备方法与应用
CA3176497A1 (en) 2020-05-07 2021-11-11 Fatima MECHTA-GRIGORIOU Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy
CN111995681B (zh) * 2020-05-09 2022-03-08 华博生物医药技术（上海）有限公司 抗tigit的抗体、其制备方法和应用
BR112022024221A2 (pt) 2020-06-02 2022-12-20 Arcus Biosciences Inc Anticorpos para tigit
CN115916348A (zh) 2020-06-18 2023-04-04 基因泰克公司 使用抗tigit抗体和pd-1轴结合拮抗剂的治疗
WO2021258337A1 (en) * 2020-06-24 2021-12-30 Huahui Health Ltd. Human monoclonal antibodies against tigit for immune related diseases
CN111718415B (zh) * 2020-07-03 2021-02-23 上海洛启生物医药技术有限公司 一种抗tigit纳米抗体及其应用
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
EP4192883A4 (en) * 2020-08-05 2024-12-04 Crystal Bioscience Inc. Anti-tigit antibody and methods of use thereof
JP2023545099A (ja) 2020-10-08 2023-10-26 アフィメド ゲーエムベーハー 三重特異性バインダー
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
WO2022148781A1 (en) 2021-01-05 2022-07-14 Institut Curie Combination of mcoln activators and immune checkpoint inhibitors
EP4294948A1 (en) 2021-02-17 2023-12-27 iTeos Belgium SA Compounds, compositions and methods of treatment thereof
AU2022253351A1 (en) 2021-04-09 2023-10-12 Boehringer Ingelheim International Gmbh New scaffold for bifunctional molecules with improved properties
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
CN118871463A (zh) 2021-07-28 2024-10-29 基因泰克公司 用于治疗癌症的方法和组合物
CA3216098A1 (en) 2021-07-30 2023-02-02 Uwe Reusch Duplexbodies
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
CA3256561A1 (en) 2022-05-02 2023-11-09 Arcus Biosciences, Inc. Anti-tigit antibodies and their uses
EP4537107A2 (en) 2022-06-07 2025-04-16 Genentech, Inc. Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28
CN121358499A (zh) 2023-03-30 2026-01-16 Ose免疫疗法 靶向活化的免疫细胞以表达免疫细胞增强分子的基于脂质的纳米粒及其用途
AU2024254671A1 (en) 2023-03-30 2025-10-02 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
WO2025068461A1 (en) 2023-09-29 2025-04-03 Negio Therapeutics Guanfacine derivatives and their use in treating cancer
WO2025068452A1 (en) 2023-09-29 2025-04-03 Negio Therapeutics Guanfacine derivatives and their use in treating cancer
WO2025132831A1 (en) 2023-12-19 2025-06-26 Universite D'aix-Marseille N-heteroaryl derivatives and uses thereof for treating cancer
WO2025242836A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2025255297A1 (en) * 2024-06-05 2025-12-11 Agilent Technologies, Inc. Anti-human tigit antibodies for in vitro diagnostics
WO2025262250A1 (en) 2024-06-20 2025-12-26 Negio Therapeutics Guanfacine derivatives and their uses
WO2026068705A1 (en) 2024-09-26 2026-04-02 Ose Immunotherapeutics Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016106302A1 (en) * 2014-12-23 2016-06-30 Bristol-Myers Squibb Company Antibodies to tigit
US20160376365A1 (en) * 2015-05-28 2016-12-29 Oncomed Pharmaceuticals, Inc. Tigit-binding agents and uses thereof
WO2017030823A2 (en) * 2015-08-14 2017-02-23 Merck Sharp & Dohme Corp. Anti-tigit antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2916681A1 (en) * 2013-07-16 2015-01-22 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
WO2015073682A1 (en) * 2013-11-13 2015-05-21 Oregon Health And Science University Methods of detecting cells latently infected with hiv
CA2994858C (en) * 2015-09-25 2024-01-23 Genentech, Inc. Anti-tigit antibodies and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016106302A1 (en) * 2014-12-23 2016-06-30 Bristol-Myers Squibb Company Antibodies to tigit
US20160376365A1 (en) * 2015-05-28 2016-12-29 Oncomed Pharmaceuticals, Inc. Tigit-binding agents and uses thereof
WO2017030823A2 (en) * 2015-08-14 2017-02-23 Merck Sharp & Dohme Corp. Anti-tigit antibodies

Also Published As

Publication number Publication date
JP2022141910A (ja) 2022-09-29
SG11201907278VA (en) 2019-09-27
MX2023006212A (es) 2023-06-09
EP3589313A1 (en) 2020-01-08
WO2018160704A9 (en) 2019-10-17
AU2018227489B2 (en) 2023-10-19
US20210269527A1 (en) 2021-09-02
CN111050788A (zh) 2020-04-21
SG10202103227YA (en) 2021-04-29
IL268517A (en) 2019-09-26
MX2019010206A (es) 2019-12-11
AU2024200157A1 (en) 2024-01-25
AU2018227489A1 (en) 2019-08-22
KR20190123749A (ko) 2019-11-01
WO2018160704A1 (en) 2018-09-07
BR112019017550A2 (pt) 2020-04-14
US20200040082A1 (en) 2020-02-06
CA3053486A1 (en) 2018-09-07
MA47694A (fr) 2021-05-19
US20230134375A1 (en) 2023-05-04
EP3589313A4 (en) 2021-05-19
JP2024057038A (ja) 2024-04-23

Similar Documents

Publication Publication Date Title
US20230134375A1 (en) Anti-TIGIT Antibodies
US20230050440A1 (en) Anti-TIGIT Antibodies
CN112513080B (zh) Vista抗原结合分子
AU2022285741A1 (en) Anti-ccr8 antibodies and uses thereof
CA3149853A1 (en) Treatment and prevention of cancer using her3 antigen-binding molecules
KR20190039421A (ko) 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
CN120554507A (zh) 拮抗剂抗cd7抗体
KR20190099254A (ko) 항-뉴로필린 항원-결합 단백질 및 그의 사용 방법
US20250122290A1 (en) Anti-cd161 antibodies and uses thereof
AU2021325430A1 (en) Antibodies against ILT2 and use thereof
US20260098093A1 (en) Treatment and prevention of cancer using vista antigen-binding molecules
US20210277139A1 (en) Ifn-gamma-inducible regulatory t cell convertible anti-cancer (irtca) antibody and uses thereof
WO2023046979A1 (en) Treatment and prevention of cancer using vista antigen-binding molecules
HK40028734A (zh) 抗tigit抗體
RU2832673C2 (ru) Антитела, направленные против ilt2, и их применение
TW202448504A (zh) Btn3a活化抗體及免疫檢查點抑制劑之組合
HK40107037A (zh) 抗cd161抗体及其用途

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20191031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220421

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230216

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20230515